TY - JOUR
T1 - Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014
T2 - A Generalized Additive Modeling Approach
AU - Mau, Lih Wen
AU - Preussler, Jaime M.
AU - Burns, Linda J.
AU - Leppke, Susan
AU - Majhail, Navneet S.
AU - Meyer, Christa L.
AU - Mupfudze, Tatenda
AU - Saber, Wael
AU - Steinert, Patricia
AU - Vanness, David J.
N1 - Funding Information:
CIBMTR ® (Center for International Blood and Marrow Transplant Research ® ) is a research collaboration between the National Marrow Donor Program ® /Be The Match ® and the Medical College of Wisconsin. CIBMTR ® is supported primarily by Public Health Service Grant/cooperative agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/cooperative agreement 1U24HL138660 from NHLBI and NCI; contract HHSH250201700006C with the Health Resources and Services Administration/Department of Health and Human Service (HRSA/DHHS); Grants N00014-17-1-2388, N00014-17-1-2850, and N00014-18-1-2045 from the Office of Naval Research; and Grants from Adaptive Biotechnologies, Amgen, Inc., 1 anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Inc., Be the Match Foundation, bluebird bio, Inc., 1 Bristol Myers Squibb Oncology, 1 Celgene Corporation, 1 Chimerix, Inc., 1 CytoSen Therapeutics, Inc., 1 Fred Hutchinson Cancer Research Center, Gamida Cell Ltd., Gilead Sciences, Inc., HistoGenetics, Inc., Immucor, Incyte Corporation, 1 Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals, Inc., 1 Karius, Inc., Karyopharm Therapeutics, Inc., Kite Pharma, 1 Inc., Medac, GmbH, Mediware, 1 The Medical College of Wisconsin, Merck & Co., Inc., 1 Mesoblast, 1 MesoScale Diagnostics, Inc., Millennium, the Takeda Oncology Co., Miltenyi Biotec, Inc., 1 Mundipharma EDO, National Marrow Donor Program, Novartis Pharmaceuticals Corporation, PCORI, Pfizer, Inc., 1 Pharmacyclics, LLC, 1 PIRCHE AG, Sanofi Genzyme, 1 Seattle Genetics, 1 Shire, Spectrum Pharmaceuticals, Inc., St. Baldrick’s Foundation, Swedish Orphan Biovitrum, Inc., Takeda Oncology, 1 and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the US Government. The Health Services Research program is supported in part by Health Resources and Services Administration contract no. HHSH234200637018C. The views expressed in this article do not reflect the official policy or position of the Health Resources and Services Administration or the National Marrow Donor Program ® /Be The Match ® .
Publisher Copyright:
© 2020, Springer Nature Switzerland AG.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Objectives: The primary objective of this study was to predict healthcare cost trajectories for patients with newly diagnosed acute myeloid leukemia (AML) receiving allogeneic hematopoietic cell transplantation (alloHCT), as a function of days since chemotherapy initiation, days relative to alloHCT, and days before death or last date of insurance eligibility (LDE). An exploratory objective examined patients with AML receiving chemotherapy only. Methods: We used Optum’s de-identified Clinformatics® Data Mart Database to construct cumulative cost trajectories from chemotherapy initiation to death or LDE (through 31 December 2014) for US patients aged 20–74 years diagnosed between 1 March 2004 and 31 December 2013 (n = 187 alloHCT; n = 253 chemotherapy only). We used generalized additive modeling (GAM) to predict expected trajectories and bootstrapped confidence intervals (CIs) at user-specified intervals conditional on dates of alloHCT and death or LDE relative to chemotherapy initiation. Results: Expected costs (in 2017 values) for a hypothetical patient receiving alloHCT 60 days after chemotherapy initiation and followed for 5 years were $US572,000 (95% CI 517,000–633,000); $US119,000 (95% CI 51,000–192,000); $US102,000 (95% CI 0–285,000); $US79,000 (95% CI 0–233,000), for years 1–4, respectively, and either $US494,000 (95% CI 212,000–799,000) or $US108,000 (95% CI 0–230,000) in year 5, whether the patient died or was lost to follow-up on day 1825, respectively. Conclusions: Rates of cost accrual varied over time since chemotherapy initiation, with accelerations around the time of alloHCT and death. GAM is a potentially useful approach for imputing longitudinal costs relative to treatment initiation and one or more intercurrent, clinical, or terminal events in randomized controlled trials or registries with unrecorded costs or for dynamic decision–analytic models.
AB - Objectives: The primary objective of this study was to predict healthcare cost trajectories for patients with newly diagnosed acute myeloid leukemia (AML) receiving allogeneic hematopoietic cell transplantation (alloHCT), as a function of days since chemotherapy initiation, days relative to alloHCT, and days before death or last date of insurance eligibility (LDE). An exploratory objective examined patients with AML receiving chemotherapy only. Methods: We used Optum’s de-identified Clinformatics® Data Mart Database to construct cumulative cost trajectories from chemotherapy initiation to death or LDE (through 31 December 2014) for US patients aged 20–74 years diagnosed between 1 March 2004 and 31 December 2013 (n = 187 alloHCT; n = 253 chemotherapy only). We used generalized additive modeling (GAM) to predict expected trajectories and bootstrapped confidence intervals (CIs) at user-specified intervals conditional on dates of alloHCT and death or LDE relative to chemotherapy initiation. Results: Expected costs (in 2017 values) for a hypothetical patient receiving alloHCT 60 days after chemotherapy initiation and followed for 5 years were $US572,000 (95% CI 517,000–633,000); $US119,000 (95% CI 51,000–192,000); $US102,000 (95% CI 0–285,000); $US79,000 (95% CI 0–233,000), for years 1–4, respectively, and either $US494,000 (95% CI 212,000–799,000) or $US108,000 (95% CI 0–230,000) in year 5, whether the patient died or was lost to follow-up on day 1825, respectively. Conclusions: Rates of cost accrual varied over time since chemotherapy initiation, with accelerations around the time of alloHCT and death. GAM is a potentially useful approach for imputing longitudinal costs relative to treatment initiation and one or more intercurrent, clinical, or terminal events in randomized controlled trials or registries with unrecorded costs or for dynamic decision–analytic models.
UR - http://www.scopus.com/inward/record.url?scp=85081593666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081593666&partnerID=8YFLogxK
U2 - 10.1007/s40273-020-00891-w
DO - 10.1007/s40273-020-00891-w
M3 - Article
C2 - 32128725
AN - SCOPUS:85081593666
VL - 38
SP - 515
EP - 526
JO - PharmacoEconomics
JF - PharmacoEconomics
SN - 1170-7690
IS - 5
ER -